German cancer statistics 2004

Abstract

BackgroundFor years the Robert Koch Institute (RKI) has been annually pooling and reviewing the data from the German population-based cancer registries and evaluating them together with the cause-of-death statistics provided by the statistical offices. Traditionally, the RKI periodically estimates the number of new cancer cases in Germany on the basis of the available data from the regional cancer registries in which registration is complete; this figure, in turn, forms the basis for further important indicators.MethodsThis article gives a brief overview of current indicators - such as incidence, prevalence, mortality, survival rates - on the most common types of cancer, as well as important ratios on the risks of developing and dying of cancer in Germany.ResultsAccording to the latest estimate, there were a total of 436,500 new cancer cases in Germany in 2004. The most common cancer in men is prostate cancer with over 58,000 new cases per annum, followed by colorectal and lung cancer. In women, breast cancer remains the most common cancer with an estimated 57,000 new cases every year, also followed by colorectal cancer. These and further findings on selected cancer sites can be found in the current brochure on "Cancer in Germany", which is regularly published by the RKI together with the Association of Population-based Cancer Registries in Germany (GEKID). In addition, the RKI made cancer-prevalence estimates and calculated current morbidity and mortality risks at the federal level for the first time. According to these figures, the 5-year partial prevalence - i.e. the total number of cancer patients diagnosed over the past five years who are currently still living - exceeds 600,000 in men; the figure is about the same among women. Here, too, the most common cancers are prostate cancer in men and breast cancer in women. The lifetime risk of developing cancer, which is more related to the individual, is estimated to be higher among men (48.5%) than among women (40.3%). In roughly rounded figures, therefore, about every second person in Germany develops cancer in the course of their lives. One in four men and one in five women die of cancer.ConclusionsIn recent years, population-based cancer registration in Germany has come significantly closer to the aim of the complete, nationwide coverage of cancer. The continuous improvements in the data situation help describe cancer development in Germany.

Die künftige Entwicklung der Erkrankungszahlen von Darmkrebs und Lungenkrebs

“…Allerdings spielen für die Entwicklung von Erkrankungshäufigkeiten viele weitere Faktoren eine Rolle. Inzidenzraten für verschiedene Tumorlokalisationen verändern sich im Laufe der Zeit in einer gegebenen Region [15,16] …”

Co-expression of FOXL1 and PP2A inhibits proliferation inducing apoptosis in pancreatic cancer cells via promoting TRAIL and reducing phosphorylated MYC

“…Surgical eradication is still the only potentially curative treatment of this malignancy, but there are only 15-20% cases indicative for surgery, because of the early occurrence of local advancement or distal metastasis (4). Five-year overall survival rate ranges from 1 to 6% (3,5,6). Even after surgical eradication plus adjuvant chemotherapy, OS rates do not exceed 30% (5,6).…”

“…Five-year overall survival rate ranges from 1 to 6% (3,5,6). Even after surgical eradication plus adjuvant chemotherapy, OS rates do not exceed 30% (5,6).…”

Combined PET/MRI Improves Diagnostic Accuracy in Patients with Prostate Cancer: A Prospective Diagnostic Trial

“…It is, however, not the leading cause of cancer-related deaths, predominantly due to the fact that prostate cancer is a heterogeneous neoplasm concerning its aggressiveness, with peak diagnosis at the age of 69 years (1,2). Nevertheless, the slow growing as well as the aggressive cases of this cancer (3) require tumor-and patient-adapted treatment strategies.…”